OSE Immunotherapeutics (France)

OSE Immunotherapeutics (France)

Open Access statistics for OSE Immunotherapeutics (France), France, covering academic research published from 2000 to 2023.

Open Access statistics for OSE Immunotherapeutics (France), France, covering academic research published from 2000 to 2023. Read More.


Open Access Percentage

67%


Total
Publications

123


Total Open
Publications

82


Total
Citations

2.1K


Open Access
Percentage

67%


Total
Publications

123


Total Open
Publications

82


Total
Citations

2.1K

Website

download

Breakdown

23% 38% 6% 33%

Publisher Open

23%

Both

38%

Other Platform Open

6%

Closed

33%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

02468101214161820Total Publications
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

46%OA Journal

OA Journal 46%

34

Hybrid 25%

19

No Guarantees 29%

22

Other Platform Open

Domain 78%

42

Institution 54%

29

Other Internet 30%

16

Public 13%

7

Preprint 7%

4

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
42
Europe PMC
Domain
23
Le Centre pour la Communication Scientifique Directe - HAL - Diderot
Institution
22
CCSD (Centre pour la Communication Scientifique Directe) - HAL - Nantes Université
Other Internet
11
Le Centre pour la Communication Scientifique Directe - HAL - Université de Nantes
Institution
10
Le Centre pour la Communication Scientifique Directe - HAL - Inria
Institution
10
Semantic Scholar
Public
6
Le Centre pour la Communication Scientifique Directe - HAL - Inserm
Institution
6
Le Centre pour la Communication Scientifique Directe - HAL - memSIC
Other Internet
5
Le Centre pour la Communication Scientifique Directe - HAL - Université Paris Descartes
Institution
4
1 / 4

Data updated 17 June 2024

Share

Share

Share